Experiences with benzodiazepine use, tapering, and discontinuation: an Internet survey
Therapeutic Advances in Psychopharmacology · 2022-01 · 12
DOI: 10.1177/20451253221082386 ↗Kurz gefasst
Fachartikel in der Zeitschrift Therapeutic Advances in Psychopharmacology, online erschienen am 25.04.2022. Verfasst von Alistair J Reid Finlayson und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry and Behavioral Sciences, Vanderbilt Psychiatric Hospital, Vanderbilt University Medical Center, Suite 3010, 1601 23rd Avenue…. Die Arbeit wurde bisher 38-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
Over 92 million prescriptions for benzodiazepines are dispensed in the United States annually, yet little is known about the experiences of those taking and discontinuing them.
Objective
The aim of this study is to assess the experiences of those taking, tapering, or having discontinued benzodiazepines.
Methods
An online survey ( n = 1207) elicited information about benzodiazepine use, including long-term use, tapering, discontinuation, and withdrawal symptoms.
Results
Symptoms associated with benzodiazepine use, tapering, and discontinuation were numerous and ranged from symptoms such as anxiety, insomnia, and nervousness to digestive problems, irregular heart rhythms, uncontrollable anger, photosensitivity, balance problems, and others. When asked how benzodiazepine symptoms affected their lives, 82.9% reported work problems, 86.3% had problems with social interactions and friendships, and 88.8% had problems with fun, recreation, and hobbies. Suicidal thoughts or attempted suicide was reported by 54.4%, and 46.8% said benzodiazepines caused lost employment. Most of the respondents for whom benzodiazepines were prescribed (76.2%) stated they had not been informed that benzodiazepines were indicated for short-term use only and that discontinuation might be difficult. About a third (31.5%) reported food allergies and/or seasonal allergies that occurred only after benzodiazepine use.
Conclusion
The trajectory of those who taper or discontinue benzodiazepines is unpredictable, and many patients experience a range of protracted and severe symptoms, even years after benzodiazepines were completely discontinued. Greater awareness is needed for both prescribers and patients about the potential for a difficult withdrawal from benzodiazepines.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Psychiatry and Behavioral Sciences, Vanderbilt Psychiatric Hospital, Vanderbilt University Medical Center, Suite 3010, 1601 23rd Avenue South, Nashville, TN 37212, USA.
- University of Southern California, Los Angeles, CA, USA.
- Benzodiazepine Information Coalition, Midvale, UT, USA.
- Benzodiazepine Action Work Group, Colorado Consortium for Prescription Drug Abuse Prevention, Aurora, CO, USA.
- Departments of Psychiatry and Behavioral Sciences & Pharmacology, Vanderbilt University Medical Center, Nashville, TN, USA.
ORCID-Profile: Alistair J Reid Finlayson
Zitieren
APA
Reid Finlayson, A. J., Macoubrie, J., Huff, C., Foster, D. E., & Martin, P. R. (2022). Experiences with benzodiazepine use, tapering, and discontinuation: an Internet survey. Therapeutic Advances in Psychopharmacology, 12. https://doi.org/10.1177/20451253221082386
Vancouver
Reid Finlayson AJ, Macoubrie J, Huff C, Foster DE, Martin PR. Experiences with benzodiazepine use, tapering, and discontinuation: an Internet survey. Therapeutic Advances in Psychopharmacology. 2022;12. doi:10.1177/20451253221082386
BibTeX
@article{ReidFinlayson2022,
author = {Reid Finlayson, Alistair J and Macoubrie, Jane and Huff, Christy and Foster, Darren E and Martin, Peter R},
title = {Experiences with benzodiazepine use, tapering, and discontinuation: an Internet survey},
journal = {Therapeutic Advances in Psychopharmacology},
year = {2022},
volume = {12},
doi = {10.1177/20451253221082386}
}
EUVIMED